More Phase 3 disappointment in Alzheimer’s disease
Alzheimer’s underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
